What does hemangeol — payments to acquire marketing rights mean?

This metric represents the capitalized or expensed payments made to secure the exclusive rights to market and distribute a specific pharmaceutical product. It reflects the upfront or milestone-based investment required to gain commercial access to a drug's intellectual property or distribution channels. Monitoring this helps investors understand the cost structure of product portfolio expansion.

Eton Pharmaceuticals, Inc. ETON Hemangeol — Payments To Acquire Marketing Rights

Similar metrics at other companies

LIFPayments For Escrow, Business Acquisition

$675K—

XOMAPayment To Acquire Intellectual Property Net

-$5.04M—

DLBPayments To Acquire Intangible Assets, Net Of Holdbacks For Indemnifications

$37.03M—

NETPayment Of Indemnity Holdback

$100K—

ENOVPurchase of royalty interest

$0-100%

WELLPayments for hedge

$47.22M+5,523%

Other financials

Income statement

See full

Revenue$24.3M+40.4%

Gross profit$14.7M+49.4%

Operating income$2.4M+614%

Net income$1.6M+199%

EPS (diluted)$0.05+183%

Balance sheet

See full

Cash & equivalents$19.7M+12.9%

Total debt$31.3M+3.7%

Total equity$30.6M+25.2%

Total assets$97.7M+16.3%

Cash flow

See full

Operating cash flow$7.4M+254%

CapEx$75.0K—

Free cash flow$7.3M+251%

Valuation

See full

Market cap$953.8M+162%

Enterprise value$965.4M+156%

P/S11×+3.4×

Profitability

See full

Gross margin54.8%-3.7pp

Operating margin-15.1%—

Net margin-9.5%-2.7pp

FCF margin17.1%—

Returns & leverage

See full

Return on equity-34.2%+0.9pp

Debt / equity1×-0.2×

Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept eton:PaymentsToAcquireMarketingRights.

The official record: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s hemangeol — payments to acquire marketing rights.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s hemangeol — payments to acquire marketing rights?: Eton Pharmaceuticals, Inc. (ETON) reported hemangeol — payments to acquire marketing rights of $14M in Q1 2026.
What does hemangeol — payments to acquire marketing rights mean?: This metric represents the capitalized or expensed payments made to secure the exclusive rights to market and distribute a specific pharmaceutical product. It reflects the upfront or milestone-based investment required to gain commercial access to a drug's intellectual property or distribution channels. Monitoring this helps investors understand the cost structure of product portfolio expansion.